IMA
ImageneBioยทNASDAQ
--
--(--)
--
--(--)
IMA Profile
Imagenebio, Inc.
A new cancer therapy focused on developing key signaling pathways that drive cancer formation and spread
Biological Technology
03/02/2016
03/26/2021
NASDAQ Stock Exchange
9
12-31
Common stock
12526 High Bluff Drive
Suite 345
San Diego
California 92130
--
ImageneBio, Inc., was incorporated as a Delaware corporation on March 2, 2016 and is headquartered in Boston, Massachusetts. The company is a targeted oncology company focused on developing novel cancer therapies targeting the critical signaling pathways that drive cancer formation and spread. The company's projects focus on key cancer-driven pathways that are well validated in the scientific literature but lack approved or effective treatments, and thus have the potential to address highly unmet medical needs. By leveraging a deep understanding of discovery chemistry, translational science and patient-centered drug development, the company has established an in-depth pipeline of wholly owned and partnered projects focused on gene-defined or biomarker-driven cancers, able to target specific patient groups that the company believes are most likely to respond to the treatment of product candidates. Since commencing operations in 2016, the company has discovered or developed five oncology programs, including four product candidates in IND research or clinical development.
